Aehr Test Systems (AEHR)
NASDAQInformation TechnologySemiconductorsSnapshot 2026-09-04
$86.26+13.10%
Close 2026-09-04 · 1-day change
NASDAQInformation TechnologySemiconductorsSnapshot 2026-09-04
Intact: The reason to own it still holds.
Aehr Test Systems aims for $25M-$30M revenue in fiscal 2026. The company is pushing AI-focused wafer test products, which could drive growth. They raised $60M in equity to support capital needs. If execution improves, losses could narrow as EPS guidance suggests.
Revenue is expected to decline about 16% per analysts. The company is loss-making with EPS below guidance recently. The recent 42% share price drop reflects market doubts on recovery. Execution risks and weak demand could keep losses and revenue down.
The market expects about 16% revenue decline and loss-making results. Our fair value is near $38, slightly above the current price, reflecting some optionality but also risks. We see the market as pricing in a tough near-term outlook.
Breaks if: Capital raised is not used to improve operations or growth
Breaks if: EPS loss exceeds -$0.09 in FY 2026
Breaks if: revenue falls below $25M in FY 2026
This is not a price target or investment advice.
A long-form read on the 1–3 year hold thesis. It updates when the weekly evidence changes.
This investment represents a speculative growth opportunity. The company aims for substantial revenue growth and profitability improvement, but faces high risks and mixed recent performance.
The market appears to have priced in a low level of execution quality, with a slight expectations gap. AEHR is currently valued at a premium compared to its peers, indicating that investors may expect future improvements.
Management is on track to achieve strong revenue growth, projecting fiscal 2027 revenue between $130 million and $150 million. However, profitability improvements are mixed, as the company is still early in its delivery on profitability targets.
The long-term thesis hinges on management's ability to meet revenue and profitability targets. Additionally, external factors like Federal Reserve interest rate decisions and performance of sector leaders could significantly impact AEHR's trajectory.
In the next 1 to 3 years, AEHR's success will depend on execution and external market conditions. Not investment advice.
The most important moves since the prior daily snapshot.
Yes, our read has strengthened. The latest earnings beat supports this view. Jefferies also projected strong revenue growth with guidance of $130 million to $150 million for FY 2027. There are no new threats to the thesis.
as of 2026-09-04
Review the evidence to watch, what would become a concern, and what would make it less concerning.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.